BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 20483197)

  • 1. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.
    van de Waterbeemd B; Streefland M; van der Ley P; Zomer B; van Dijken H; Martens D; Wijffels R; van der Pol L
    Vaccine; 2010 Jul; 28(30):4810-6. PubMed ID: 20483197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
    Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
    Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants.
    van der Ley P; van den Dobbelsteen G
    Hum Vaccin; 2011 Aug; 7(8):886-90. PubMed ID: 21785281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
    Holst J
    Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
    Sanders H; Feavers IM
    Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic analysis of Neisseria lactamica and N eisseria meningitidis outer membrane vesicle vaccine antigens.
    Vaughan TE; Skipp PJ; O'Connor CD; Hudson MJ; Vipond R; Elmore MJ; Gorringe AR
    Vaccine; 2006 Jun; 24(25):5277-93. PubMed ID: 16682101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
    Bai X; Borrow R
    Expert Rev Vaccines; 2010 Oct; 9(10):1203-17. PubMed ID: 20923270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
    Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
    mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
    Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
    Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives.
    Arigita C; Luijkx T; Jiskoot W; Poelen M; Hennink WE; Crommelin DJ; Ley Pv; Els Cv; Kersten GF
    Vaccine; 2005 Oct; 23(43):5091-8. PubMed ID: 15993990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.
    Matthias KA; Reveille A; Connolly KL; Jerse AE; Gao YS; Bash MC
    Vaccine; 2020 Feb; 38(10):2396-2405. PubMed ID: 32037226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
    Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
    FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254.
    Vipond C; Suker J; Jones C; Tang C; Feavers IM; Wheeler JX
    Proteomics; 2006 Jun; 6(11):3400-13. PubMed ID: 16645985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry.
    Uli L; Castellanos-Serra L; Betancourt L; Domínguez F; Barberá R; Sotolongo F; Guillén G; Pajón Feyt R
    Proteomics; 2006 Jun; 6(11):3389-99. PubMed ID: 16673438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
    Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
    Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract]   [Full Text] [Related]  

  • 20. Induction of immune responses by purified outer membrane protein complexes from Neisseria meningitidis.
    Marzoa J; Sánchez S; Costoya L; Diéguez-Casal E; Freixeiro P; Brookes C; Allen L; Taylor S; Gorringe AR; Ferreirós CM; Criado MT
    Vaccine; 2012 Mar; 30(13):2387-95. PubMed ID: 21911024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.